News
TRDA
4.690
-4.09%
-0.200
Entrada Therapeutics price target lowered to $10 from $11 at Roth Capital
TipRanks · 4d ago
Entrada Therapeutics Q3 EPS $(0.94) Beats $(1.01) Estimate, Sales $905.000K Miss $5.871M Estimate
Benzinga · 4d ago
Entrada Therapeutics GAAP EPS of -$0.94 beats by $0.07, revenue of $0.90M misses by $4.97M
Seeking Alpha · 4d ago
Entrada Therapeutics reports Q3 EPS (94c), consensus (99c)
TipRanks · 4d ago
Weekly Report: what happened at TRDA last week (1026-1030)?
Weekly Report · 11/02 09:15
Weekly Report: what happened at TRDA last week (1019-1023)?
Weekly Report · 10/26 09:15
Entrada Therapeutics appoints Linea Aspesi as chief people officer
TipRanks · 10/21 11:05
Press Release: Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Dow Jones · 10/21 11:00
Analysts Offer Insights on Healthcare Companies: SanBio Co (OtherSNBIF), Oruka Therapeutics (ORKA) and Entrada Therapeutics Inc (TRDA)
TipRanks · 10/19 10:50
Weekly Report: what happened at TRDA last week (1012-1016)?
Weekly Report · 10/19 09:15
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 10/16 07:30
Noteworthy Thursday Option Activity: TRDA, JBS, MCRI
NASDAQ · 10/15 19:45
What's Going On With Entrada Therapeutics Stock Wednesday?
Benzinga · 10/14 16:47
Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level
NASDAQ · 10/14 13:08
Entrada Therapeutics reports positive ENTR-601-45 trial results
TipRanks · 10/14 12:20
Entrada Reports Positive Topline Data From Cohort 1 Of Phase 1/2 ELEVATE-45-201 Study Of ENTR-601-45
NASDAQ · 10/14 11:30
Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study
TipRanks · 10/14 11:11
Entrada Therapeutics Announces Independent Data Monitoring Committee Review Of All Available Safety And PK Data From The Eight Participants Enrolled In Cohort 2 Of The Double-Blind, Placebo-Controlled, Multiple Ascending Dose Portion of ELEVATE-44-201
Benzinga · 10/14 11:07
Weekly Report: what happened at TRDA last week (1005-1009)?
Weekly Report · 10/12 09:16
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Seeking Alpha · 10/10 06:47
More
Webull provides a variety of real-time TRDA stock news. You can receive the latest news about Entrada Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.